Cencora Inc (COR) Stock Forecast & Price Target

Cencora is well positioned by its dominant U.S. wholesale scale, with more than 90% industry share alongside McKesson and Cardinal Health, while its expansion into higher-margin services such as patient support, data analytics, and global specialty logistics improves the quality of earnings beyond pure distribution. Specialty-pharma exposure, including biosimilar penetration, new specialty drug approvals, and gene therapy categories expected to come to market in 2026, should support above-market revenue growth, modest margin expansion, and operating income accretion even as IRA and MFN headwinds pressure pricing. Its 2021 acquisition of Alliance Healthcare broadens international reach, and the integrated model should help offset regulatory risks while sustaining resilient demand across pharmacies, hospitals, and healthcare providers.

Cencora is viewed negatively because its core pharmaceutical distribution business faces slowing growth and margin pressure from IRA and MFN-related pricing reforms, with ~ $28B of Medicare drug spend subject to 40–60% cuts starting in 2028. Its heavy customer concentration, exposure to contract renewals, and reliance on low-single-digit gross-margin distribution leave earnings vulnerable if McKesson or Cardinal Health take share or if direct-to-patient and PBM-owned specialty channels intensify. On top of that, the MWI-Covetrus deal faces rising FTC scrutiny and could be blocked or delayed, while cybersecurity, supply-chain disruptions, and international currency or European pricing controls add further volatility.